The VITamin D and OmegA-3 TriaL (VITAL): Rationale and design of a large randomized controlled trial of vitamin D and marine omega-3 fatty acid supplements for the primary prevention of cancer and cardiovascular disease

Contemporary Clinical Trials

Volumn 33, Issue 1, 2012, Pages 159-171

  Manson, JoAnn E ^a,b   Bassuk, Shari S ^a   Lee, I Min ^a,b   Cook, Nancy R ^a,b   Albert, Michelle A ^a   Gordon, David ^a   Zaharris, Elaine ^a   MacFadyen, Jean G ^a   Danielson, Eleanor ^a   Lin, Jennifer ^a   Zhang, Shumin M ^a   Buring, Julie E ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Cancer; Cardiovascular disease; Cholecalciferol; Omega 3 fatty acids; Primary prevention; Randomized controlled trial; Vitamin D

Indexed keywords

COLECALCIFEROL; OMEGA 3 FATTY ACID; PLACEBO;

ADULT; ARTICLE; BREAST CANCER; CANCER RISK; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COLORECTAL CANCER; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DIET SUPPLEMENTATION; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HEART INFARCTION; HUMAN; HYPERCALCEMIA; IMPAIRED GLUCOSE TOLERANCE; MAJOR CLINICAL STUDY; MORTALITY; NAUSEA; NEOPLASM; NEPHROLITHIASIS; PATIENT SELECTION; PROSTATE CANCER; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; SELF REPORT; SIDE EFFECT; STROKE;

CARDIOVASCULAR DISEASES; DIETARY SUPPLEMENTS; DOUBLE-BLIND METHOD; FATTY ACIDS, OMEGA-3; FEMALE; FISH OILS; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PRIMARY PREVENTION; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; VITAMIN D; VITAMINS;

EID: 84855341899     PISSN: 15517144     EISSN: 15592030     Source Type: Journal    
DOI: 10.1016/j.cct.2011.09.009     Document Type: Article

References (120)

1. Krishnan A.V., Feldman D. Mechanisms of the anti-cancer and anti-inflammatory actions of vitamin D. Annu Rev Pharmacol Toxicol 2011, 51:311-336.
2. Deeb K.K., Trump D.L., Johnson C.S. Vitamin D signalling pathways in cancer: potential for anticancer therapeutics. Nat Rev Cancer 2007, 7:684-700.
3. Manson J.E., Bassuk S.S. Vitamin D and cardiovascular disease. Menopause Manage. 2009, 18:28-31.
4. Grant W.B. An estimate of premature cancer mortality in the U.S. due to inadequate doses of solar ultraviolet-B radiation. Cancer 2002, 94:1867-1875.
5. Grant W.B. Ecologic studies of solar UV-B radiation and cancer mortality rates. Recent Results Cancer Res 2003, 164:371-377.
6. Mizoue T. Ecological study of solar radiation and cancer mortality in Japan. Health Phys 2004, 87:532-538.
7. Zittermann A., Schleithoff S.S., Koerfer R. Putting cardiovascular disease and vitamin D insufficiency into perspective. Br J Nutr 2005, 94:483-492.
8. Giovannucci E., Liu Y., Rimm E.B., Hollis B.W., Fuchs C.S., Stampfer M.J., et al. Prospective study of predictors of vitamin D status and cancer incidence and mortality in men. J Natl Cancer Inst 2006, 98:451-459.
9. Freedman D.M., Looker A.C., Chang S.C., Graubard B.I. Prospective study of serum vitamin D and cancer mortality in the United States. J Natl Cancer Inst 2007, 99:1594-1602.
10. Pilz S., Dobnig H., Winklhofer-Roob B., Riedmuller G., Fischer J.E., Seelhorst U., et al. Low serum levels of 25-hydroxyvitamin D predict fatal cancer in patients referred to coronary angiography. Cancer Epidemiol Biomarkers Prev 2008, 17:1228-1233.
11. Gorham E.D., Garland C.F., Garland F.C., Grant W.B., Mohr S.B., Lipkin M., et al. Vitamin D and prevention of colorectal cancer. J Steroid Biochem Mol Biol 2005, 97:179-194.
12. Gorham E.D., Garland C.F., Garland F.C., Grant W.B., Mohr S.B., Lipkin M., et al. Optimal vitamin D status for colorectal cancer prevention: a quantitative meta-analysis. Am J Prev Med 2007, 32:210-216.
13. Bertone-Johnson E.R., Chen W.Y., Holick M.F., Hollis B.W., Colditz G.A., Willett W.C., et al. Plasma 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D and risk of breast cancer. Cancer Epidemiol Biomarkers Prev 2005, 14:1991-1997.
14. Lowe L.C., Guy M., Mansi J.L., Peckitt C., Bliss J., Wilson R.G., et al. Plasma 25-hydroxy vitamin D concentrations, vitamin D receptor genotype and breast cancer risk in a UK Caucasian population. Eur J Cancer 2005, 41:1164-1169.
15. Abbas S., Linseisen J., Slanger T., Kropp S., Mutschelknauss E.J., Flesch-Janys D., et al. Serum 25-hydroxyvitamin D and risk of post-menopausal breast cancer-results of a large case-control study. Carcinogenesis 2008, 29:93-99.
16. Wang T.J., Pencina M.J., Booth S.L., Jacques P.F., Ingelsson E., Lanier K., et al. Vitamin D deficiency and risk of cardiovascular disease. Circulation 2008, 117:503-511.
17. Giovannucci E., Liu Y., Hollis B.W., Rimm E.B. A prospective study of 25-hydroxyvitamin D and risk of myocardial infarction in men. Arch Intern Med 2008, 168:1174-1180.
18. Dobnig H., Pilz S., Scharnagl H., Renner W., Seelhorst U., Wellnitz B., et al. Independent association of low serum 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D levels with all-cause and cardiovascular mortality. Arch Intern Med 2008, 168:1340-1349.
19. Anderson J.L., May H.T., Horne B.D., Bair T.L., Hall N.L., Carlquist J.F., et al. Relation of vitamin D deficiency to cardiovascular risk factors, disease status, and incident events in a general healthcare population. Am J Cardiol 2010, 106:963-968.
20. Lappe J.M., Travers-Gustafson D., Davies K.M., Recker R.R., Heaney R.P. Vitamin D and calcium supplementation reduces cancer risk: results of a randomized trial. Am J Clin Nutr 2007, 85:1586-1591.
21. Lappe J.M., Heaney R.P. Calcium supplementation: results may not be generalisable. BMJ 2008, 336:403.
22. Trivedi D.P., Doll R., Khaw K.T. Effect of four monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: randomised double blind controlled trial. BMJ 2003, 326:469.
23. Prince R.L., Austin N., Devine A., Dick I.M., Bruce D., Zhu K. Effects of ergocalciferol added to calcium on the risk of falls in elderly high-risk women. Arch Intern Med 2008, 168:103-108.
24. Wactawski-Wende J., Kotchen J.M., Anderson G.L., Assaf A.R., Brunner R.L., O'Sullivan M.J., et al. Calcium plus vitamin D supplementation and the risk of colorectal cancer. N Engl J Med 2006, 354:684-696.
25. Jackson R.D., LaCroix A.Z., Gass M., Wallace R.B., Robbins J., Lewis C.E., et al. Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med 2006, 354:669-683.
26. Institute of Medicine Dietary reference intakes for calcium and vitamin D 2011, The National Academies Press, Washington DC.
27. Ross A.C., Manson J.E., Abrams S.A., Aloia J.F., Brannon P.M., Clinton S.K., et al. The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. J Clin Endocrinol Metab 2011, 96:53-58.
28. Looker A.C., Dawson-Hughes B., Calvo M.S., Gunter E.W., Sahyoun N.R. Serum 25-hydroxyvitamin D status of adolescents and adults in two seasonal subpopulations from NHANES III. Bone 2002, 30:771-777.
29. Holick M.F. Vitamin D deficiency. N Engl J Med 2007, 357:266-281.
30. Harris S.S. Vitamin D and African Americans. J Nutr 2006, 136:1126-1129.
31. Moore C.E., Murphy M.M., Holick M.F. Vitamin D intakes by children and adults in the United States differ among ethnic groups. J Nutr 2005, 135:2478-2485.
32. Martins D., Wolf M., Pan D., Zadshir A., Tareen N., Thadhani R., et al. Prevalence of cardiovascular risk factors and the serum levels of 25-hydroxyvitamin D in the United States: data from the Third National Health and Nutrition Examination Survey. Arch Intern Med 2007, 167:1159-1165.
33. Harris S.S., Dawson-Hughes B. Reduced sun exposure does not explain the inverse association of 25-hydroxyvitamin D with percent body fat in older adults. J Clin Endocrinol Metab 2007, 92:3155-3157.
34. Flegal K.M., Carroll M.D., Ogden C.L., Curtin L.R. Prevalence and trends in obesity among US adults, 1999-2008. JAMA 2010, 303:235-241.
35. Kris-Etherton P.M., Harris W.S., Appel L.J. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation 2002, 106:2747-2757.
36. Robinson J.G., Stone N.J. Antiatherosclerotic and antithrombotic effects of omega-3 fatty acids. Am J Cardiol 2006, 98:39i-49i.
37. Reiffel J.A., McDonald A. Antiarrhythmic effects of omega-3 fatty acids. Am J Cardiol 2006, 98:50i-60i.
38. Harris W.S., Miller M., Tighe A.P., Davidson M.H., Schaefer E.J. Omega-3 fatty acids and coronary heart disease risk: clinical and mechanistic perspectives. Atherosclerosis 2008, 197:12-24.
39. Lee J.H., O'Keefe J.H., Lavie C.J., Marchioli R., Harris W.S. Omega-3 fatty acids for cardioprotection. Mayo Clin Proc 2008, 83:324-332.
40. Mori T.A., Beilin L.J. Omega-3 fatty acids and inflammation. Curr Atheroscler Rep 2004, 6:461-467.
41. Mozaffarian D., Rimm E.B. Fish intake, contaminants, and human health: evaluating the risks and the benefits. JAMA 2006, 296:1885-1899.
42. He K., Song Y., Daviglus M.L., Liu K., Van Horn L., Dyer A.R., et al. Accumulated evidence on fish consumption and coronary heart disease mortality: a meta-analysis of cohort studies. Circulation 2004, 109:2705-2711.
43. Whelton S.P., He J., Whelton P.K., Muntner P. Meta-analysis of observational studies on fish intake and coronary heart disease. Am J Cardiol 2004, 93:1119-1123.
44. Lemaitre R.N., King I.B., Mozaffarian D., Kuller L.H., Tracy R.P., Siscovick D.S. n-3 Polyunsaturated fatty acids, fatal ischemic heart disease, and nonfatal myocardial infarction in older adults: the cardiovascular health study. Am J Clin Nutr 2003, 77:319-325.
45. Iso H., Kobayashi M., Ishihara J., Sasaki S., Okada K., Kita Y., et al. Intake of fish and n3 fatty acids and risk of coronary heart disease among Japanese: the Japan Public Health Center-Based (JPHC) Study Cohort I. Circulation 2006, 113:195-202.
46. He K., Rimm E.B., Merchant A., Rosner B.A., Stampfer M.J., Willett W.C., et al. Fish consumption and risk of stroke in men. JAMA 2002, 288:3130-3136.
47. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. Lancet 1999, 354:447-455. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico.
48. Yokoyama M., Origasa H., Matsuzaki M., Matsuzawa Y., Saito Y., Ishikawa Y., et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet 2007, 369:1090-1098.
49. MacLean C.H., Newberry S.J., Mojica W.A., Khanna P., Issa A.M., Suttorp M.J., et al. Effects of omega-3 fatty acids on cancer risk: a systematic review. JAMA 2006, 295:403-415.
50. Norat T., Bingham S., Ferrari P., Slimani N., Jenab M., Mazuir M., et al. Meat, fish, and colorectal cancer risk: the European Prospective Investigation into Cancer and Nutrition. J Natl Cancer Inst 2005, 97:906-916.
51. Kato I., Akhmedkhanov A., Koenig K., Toniolo P.G., Shore R.E., Riboli E. Prospective study of diet and female colorectal cancer: the New York University Women's Health Study. Nutr Cancer 1997, 28:276-281.
52. Hall M.N., Chavarro J.E., Lee I.M., Willett W.C., Ma J. A 22-year prospective study of fish, n-3 fatty acid intake, and colorectal cancer risk in men. Cancer Epidemiol Biomarkers Prev 2008, 17:1136-1143.
53. Hooper L., Thompson R.L., Harrison R.A., Summerbell C.D., Ness A.R., Moore H.J., et al. Risks and benefits of omega 3 fats for mortality, cardiovascular disease, and cancer: systematic review. BMJ 2006, 332:752-760.
54. Larsson S.C., Kumlin M., Ingelman-Sundberg M., Wolk A. Dietary long-chain n-3 fatty acids for the prevention of cancer: a review of potential mechanisms. Am J Clin Nutr 2004, 79:935-945.
55. American Cancer Society Cancer facts & figures for African Americans 2009-2010 2009, American Cancer Society, Atlanta.
56. Harris S.S. Does vitamin D deficiency contribute to increased rates of cardiovascular disease and type 2 diabetes in African Americans. Am J Clin Nutr 2011, 93:1175S-1178S.
57. Institute of Medicine Food and Nutrition Board Dietary reference intakes: calcium, phosphorous, magnesium, vitamin D and fluoride 1999, National Academies Press, Washington DC.
58. Bischoff-Ferrari H.A., Giovannucci E., Willett W.C., Dietrich T., Dawson-Hughes B. Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple health outcomes. Am J Clin Nutr 2006, 84:18-28.
59. Dawson-Hughes B., Heaney R.P., Holick M.F., Lips P., Meunier P.J., Vieth R. Estimates of optimal vitamin D status. Osteoporos Int 2005, 16:713-716.
60. Aloia J.F., Patel M., Dimaano R., Li-Ng M., Talwar S.A., Mikhail M., et al. Vitamin D intake to attain a desired serum 25-hydroxyvitamin D concentration. Am J Clin Nutr 2008, 87:1952-1958.
61. Harris W.S. International recommendations for consumption of long-chain omega-3 fatty acids. J Cardiovasc Med (Hagerstown) 2007, 8(Suppl 1):S50-S52.
62. Hathcock J.N., Shao A., Vieth R., Heaney R. Risk assessment for vitamin D. Am J Clin Nutr 2007, 85:6-18.
63. Bolland M.J., Barber P.A., Doughty R.N., Mason B., Horne A., Ames R., et al. Vascular events in healthy older women receiving calcium supplementation: randomised controlled trial. BMJ 2008, 336:262-266.
64. Radimer K., Bindewald B., Hughes J., Ervin B., Swanson C., Picciano M.F. Dietary supplement use by US adults: data from the National Health and Nutrition Examination Survey, 1999-2000. Am J Epidemiol 2004, 160:339-349.
65. Stacewicz-Sapuntzakis M., Borthakur G., Burns J.L., Bowen P.E. Correlations of dietary patterns with prostate health. Mol Nutr Food Res 2008, 52:114-130.
66. Ahn J., Albanes D., Peters U., Schatzkin A., Lim U., Freedman M., et al. Dairy products, calcium intake, and risk of prostate cancer in the prostate, lung, colorectal, and ovarian cancer screening trial. Cancer Epidemiol Biomarkers Prev 2007, 16:2623-2630.
67. Park Y., Mitrou P.N., Kipnis V., Hollenbeck A., Schatzkin A., Leitzmann M.F. Calcium, dairy foods, and risk of incident and fatal prostate cancer: the NIH-AARP Diet and Health Study. Am J Epidemiol 2007, 166:1270-1279.
68. Wang C, Chung M, Lichentstein A, Balk E, Kupelnick B, DeVine D, et al. Effects of Omega-3 Fatty Acids on Cardiovascular Disease. Summary, Evidence Report/Technology Assessment No. 94. AHRQ Publication No. 04-E009-1. Rockville MD: Agency for Healthcare Research and Quality. March 2004. Available at http:/www.ahrq.gov/clinic/epcsums/o3cardsum.pdf. Accessed on March 24, 2011.
69. Simopoulos A.P. Evolutionary aspects of diet, the omega-6/omega-3 ratio and genetic variation: nutritional implications for chronic diseases. Biomed Pharmacother 2006, 60:502-507.
70. Kris-Etherton P.M., Taylor D.S., Yu-Poth S., Huth P., Moriarty K., Fishell V., et al. Polyunsaturated fatty acids in the food chain in the United States. Am J Clin Nutr 2000, 71:179S-188S.
71. Harris W.S. The omega-6/omega-3 ratio and cardiovascular disease risk: uses and abuses. Curr Atheroscler Rep 2006, 8:453-459.
72. Stanley J.C., Elsom R.L., Calder P.C., Griffin B.A., Harris W.S., Jebb S.A., et al. UK Food Standards Agency Workshop Report: the effects of the dietary n-6:n-3 fatty acid ratio on cardiovascular health. Br J Nutr 2007, 98:1305-1310.
73. Harris W.S., Poston W.C., Haddock C.K. Tissue n-3 and n-6 fatty acids and risk for coronary heart disease events. Atherosclerosis 2007, 193:1-10.
74. Mozaffarian D., Ascherio A., Hu F.B., Stampfer M.J., Willett W.C., Siscovick D.S., et al. Interplay between different polyunsaturated fatty acids and risk of coronary heart disease in men. Circulation 2005, 111:157-164.
75. Department of Health and Human Services, U.S.Food and Drug Administration Substances affirmed as generally recognized as safe: menhaden oil. Federal Register 1997, Vol 62:30751-30757. June 5, 1997, No 108, 21 CFR Part 184 [Docket No. 86G-0289].
76. Harris W.S. Expert opinion: omega-3 fatty acids and bleeding-cause for concern?. Am J Cardiol 2007, 99:44C-46C.
77. Bays H.E. Safety considerations with omega-3 fatty acid therapy. Am J Cardiol 2007, 99:35C-43C.
78. Ridker P.M., Cook N.R., Lee I.M., Gordon D., Gaziano J.M., Manson J.E., et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 2005, 352:1293-1304.
79. Gaziano J.M., Glynn R.J., Christen W.G., Kurth T., Belanger C., MacFadyen J., et al. Vitamins E and C in the prevention of prostate and total cancer in men: the Physicians' Health Study II randomized controlled trial. JAMA 2009, 301:52-62.
80. Cook N.R., Albert C.M., Gaziano J.M., Zaharris E., MacFadyen J., Danielson E., et al. A randomized factorial trial of vitamins C and E and beta carotene in the secondary prevention of cardiovascular events in women: results from the Women's Antioxidant Cardiovascular Study. Arch Intern Med 2007, 167:1610-1618.
81. Steering Committee of the Physicians' Health Study Research Group Final report on the aspirin component of the ongoing Physicians' Health Study. N Engl J Med 1989, 321:129-135.
82. Lang J.M., Buring J.E., Rosner B., Cook N., Hennekens C.H. Estimating the effect of the run-in on the power of the Physicians' Health Study. Stat Med 1991, 10:1585-1593.
83. Talwar S.A., Aloia J.F., Pollack S., Yeh J.K. Dose response to vitamin D supplementation among postmenopausal African American women. Am J Clin Nutr 2007, 86:1657-1662.
84. Hollis B.W., Napoli J.L. Improved radioimmunoassay for vitamin D and its use in assessing vitamin D status. Clin Chem 1985, 31:1815-1819.
85. Hollis B.W., Kamerud J.Q., Selvaag S.R., Lorenz J.D., Napoli J.L. Determination of vitamin D status by radioimmunoassay with an 125I-labeled tracer. Clin Chem 1993, 39:529-533.
86. Vitamin D Metabolites Quality Assurance Program National Institute of Standards and Technology, Accessed on March 24, 2011. http://www.nist.gov/mml/analytical/vitdqap.cfm.
87. Rimm E.B., Giovannucci E.L., Stampfer M.J., Colditz G.A., Litin L.B., Willett W.C. Reproducibility and validity of an expanded self-administered semiquantitative food frequency questionnaire among male health professionals. Am J Epidemiol 1992, 135:1114-1126.
88. Feskanich D., Rimm E.B., Giovannucci E.L., Colditz G.A., Stampfer M.J., Litin L.B., et al. Reproducibility and validity of food intake measurements from a semiquantitative food frequency questionnaire. J Am Diet Assoc 1993, 93:790-796.
89. Salvini S., Hunter D.J., Sampson L., Stampfer M.J., Colditz G.A., Rosner B., et al. Food-based validation of a dietary questionnaire: the effects of week-to-week variation in food consumption. Int J Epidemiol 1989, 18:858-867.
90. Jacques P.F., Sulsky S.I., Sadowski J.A., Phillips J.C., Rush D., Willett W.C. Comparison of micronutrient intake measured by a dietary questionnaire and biochemical indicators of micronutrient status. Am J Clin Nutr 1993, 57:182-189.
91. Feskanich D., Willett W.C., Colditz G.A. Calcium, vitamin D, milk consumption, and hip fractures: a prospective study among postmenopausal women. Am J Clin Nutr 2003, 77:504-511.
92. Hunter D.J., Rimm E.B., Sacks F.M., Stampfer M.J., Colditz G.A., Litin L.B., et al. Comparison of measures of fatty acid intake by subcutaneous fat aspirate, food frequency questionnaire, and diet records in a free-living population of US men. Am J Epidemiol 1992, 135:418-427.
93. Fritz A.G., Percy C., Jack A., Shanmugaratham K., Sobin L.H., Parkin M.D., et al. International Classification of Diseases for Oncology (ICD-O) 2000, World Health Organization, Geneva. Third Edition.
94. Thygesen K., Alpert J.S., White H.D. Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction. Universal definition of myocardial infarction. Circulation 2007, 116:2634-2653.
95. Adams H.P., Bendixen B.H., Kappelle L.J., Biller J., Love B.B., Gordon D.L., et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 1993, 24:35-41.
96. Satterfield S., Greco P.J., Goldhaber S.Z., Stampfer M.J., Swartz S.L., Stein E.A., et al. Biochemical markers of compliance in the Physicians' Health Study. Am J Prev Med 1990, 6:290-294.
97. Cox D.R. Regression models and life-tables. J R Stat Soc B 1972, 34:187-220.
98. Gooley T.A., Leisenring W., Crowley J., Storer B.E. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 1999, 18:695-706.
99. Putter H., Fiocco M., Geskus R.B. Tutorial in biostatistics: competing risks and multi-state models. Stat Med 2007, 26:2389-2430.
100. Fine J.P., Gray R.J. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999, 94:496-509.
101. Prentice R.L. A case-cohort design for epidemiologic cohort studies and disease prevention trials. Biometrika 1986, 73:1-11.
102. Barlow W.E. Robust variance estimation for the case-cohort design. Biometrics 1994, 50:1064-1072.
103. Borgan O., Langholz B., Samuelsen S.O., Goldstein L., Pogoda J. Exposure stratified case-cohort designs. Lifetime Data Anal 2000, 6:39-58.
104. Holick M.F., Vitamin D. for health and in chronic kidney disease. Semin Dial 2005, 18:266-275.
105. Hozawa A., Folsom A.R., Sharrett A.R., Chambless L.E. Absolute and attributable risks of cardiovascular disease incidence in relation to optimal and borderline risk factors. Arch Intern Med 2007, 167:573-579.
106. Fast Stats: An interactive tool for access to SEER cancer statistics Surveillance Research Program, National Cancer Institute, Accessed on March 24, 2011. http://seer.cancer.gov/faststats.
107. Freedman L.S. Tables of the number of patients required in clinical trials using the logrank test. Stat Med 1982, 1:121-129.
108. Haybittle J.L. Repeated assessment of results in clinical trials of cancer treatment. Br J Radiol 1971, 44:793-797.
109. Peto R., Pike M.C., Armitage P., Breslow N.E., Cox D.R., Howard S.V., et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design. Br J Cancer 1976, 34:585-612.
110. Pocock S.J. Current controversies in data monitoring for clinical trials. Clin Trials 2006, 3:513-521.
111. Welsh J. Vitamin D and prevention of breast cancer. Acta Pharmacol Sin 2007, 28:1373-1382.
112. Stipp D. Fish-oil doses can be hard to swallow. Wall St J 2008 January 8, D1-D2.
113. Parker-Pope T. The miracle of vitamin D: sound science, or hype? Well blog of the New York Times Feb 1, 2010, Accessed on February 24, 2011. http://well.blogs.nytimes.com/2010/02/01/the-miracle-of-vitamin-d-sound-science-or-hype/.
114. Working group report on future clinical research directions on omega-3 fatty acids and cardiovascular disease NIH Office of Dietary Supplements, National Heart Lung and Blood Institute, June 2, 2004 Bethesda MD. Available at, Accessed on March 24, 2011. http://www.nhlbi.nih.gov/meetings/workshops/omega-3/omega-3-rpt.htm.
115. Kris-Etherton P.M., Lichtenstein A.H., Howard B.V., Steinberg D., Witztum J.L. Antioxidant vitamin supplements and cardiovascular disease. Circulation 2004, 110:637-641.
116. Lee I.M., Cook N.R., Gaziano J.M., Gordon D., Ridker P.M., Manson J.E., et al. Vitamin E in the primary prevention of cardiovascular disease and cancer: the Women's Health Study: a randomized controlled trial. JAMA 2005, 294:56-65.
117. Bjelakovic G., Nikolova D., Gluud L.L., Simonetti R.G., Gluud C. Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis. JAMA 2007, 297:842-857.
118. Byers T. Anticancer vitamins du jour-The ABCED's so far. Am J Epidemiol 2010, 172:1-3.
119. Bolland M.J., Avenell A., Baron J.A., Grey A., MacLennan G.S., Gamble G.D., et al. Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis. BMJ 2010, 341:c3691.
120. Toner C.D., Davis C.D., Milner J.A. The vitamin D and cancer conundrum: aiming at a moving target. J Am Diet Assoc 2010, 110:1492-1500.